BC Week In Review | Feb 21, 2011
Clinical News

DermX: Phase I started

ProCertus began an open-label, U.S. Phase I trial to evaluate 1.6 mL topical DermX administered prior to radiation therapy in about 12 post-surgical breast cancer patients. ProCertus BioPharm Inc. , Madison, Wis.   Product: DermX  ...
Items per page:
1 - 1 of 1